Preparation method and application of immune cell with anti-tumor function

By optimizing the culture method and specific culture medium, combined with the extract of angelica numbus extract, the immune cells are activated and expanded, and the problems of insufficient efficacy and poor safety of immune cell therapy in the prior art have been solved, which has significantly improved the anti-tumor function of immune cells and is clinically improved. Provides efficient cellular support.

CN119060952AInactive Publication Date: 2024-12-03深圳伊甸赛尔生物科技有限公司
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411566232.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-05
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing immune cell therapy technology has problems such as insufficient efficacy, poor safety and insufficient individual adaptability, and it is difficult to significantly improve the number and quality of immune cells and enhance their anti-tumor function.

Method used

Using optimized culture methods and specific design culture medium, combined with the preparation process of angelica nigiri extract, the addition of tumor cell lysates to the first culture medium and the second culture medium to activate and amplify immune cells and improve the Its proportion, survival rate and expansion factor enhance the anti-tumor function of immune cells.

Benefits of technology

It significantly increased the proportion, cell viability and expansion multiple of NK cells, improved the culture effect and anti-tumor effect of immune cells, and provided efficient cell source and technical support for clinical treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
Patent Text Reader

Abstract

The invention discloses a preparation method and application of immune cells with an anti-tumor function, and belongs to the technical field of biological medicines.The preparation method comprises the following steps that S1, a peripheral blood sample is collected, mononuclear cells are separated, cleaned and counted, and cell activity is evaluated; s2, inoculating the mononuclear cells into a bioreactor, culturing the mononuclear cells in the bioreactor for 1 day through a first culture medium, then replacing the culture medium in the bioreactor, and continuously culturing the mononuclear cells in the bioreactor for 13-15 days through a second culture medium to obtain immune cells; s3, activating and inducing the immune cells for 7 days from the fourteenth day after culture; and S4, continuing to perform multiplication culture by using a second culture medium, supplementing the culture medium every 2-3 days, and maintaining the cell density at 1.8 * 10 < 6 > cells / mL until clinical use. The problems of low immune cell culture efficiency and poor function are solved, and the anti-tumor function of the immune cells is enhanced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a method for preparing immune cells with anti-tumor function and application thereof. Background Art

[0002] Tumors are new growths formed when cells in local tissues lose normal regulation of their growth at the genetic level under the influence of various tumorigenic factors, leading to abnormal proliferation and differentiation. Once formed, new growths do not stop growing even if the cause is eliminated. Their growth is not regulated by normal physiological regulation of the body, but destroys normal tissues and organs. This is especially evident in malignant tumors. Compared with benign tumors, malignant tumors grow faster and infiltratively, are prone to bleeding, necrosis, ulcers, etc., and often metastasize to distant sites, causing weight loss, weakness, anemia, loss of appetite, fever, and severe organ damage, which ultimately leads to the death of the patient.

[0003] Malignant tumors are the first disease that seriously threatens people's lives and health. After resection surgery, radiotherapy, and chemotherapy, tumor immune cell therapy is the fourth major therapy used in clinical tumor treatment. It is an emerging tumor treatment model with significant efficacy and a new autoimmune anti-cancer treatment method. It uses biotechnology and biological agents to culture and amplify immune cells collected from the patient's body in vitro and then return them to the patient's body to stimulate and enhance the body's own immune function, thereby achieving the purpose of treating tumors. Adoptive Cell Transfer Therapy (ACT) is to collect the body's own immune cells, culture them in vitro, increase their number by thousands of times, increase the strength of defense cells, or transform immune cells to make them super police cells with enhanced targeted killing function, and then return them to the human body to kill pathogens, cancer cells, and mutated cells in the blood and tissues, break immune tolerance, and activate and enhance the body's immune ability. Immune cell therapy technology has significant advantages such as good efficacy, few or no adverse reactions, and no drug resistance. It has developed rapidly in recent years and is hailed as one of the most promising tumor treatment technologies after surgery, drug therapy, and radiotherapy. Although immune cell therapy technology has made significant progress, there are still some problems, such as insufficient efficacy, poor safety, and insufficient individual adaptability.

[0004] Therefore, there is an urgent need for a method for preparing immune cells with anti-tumor function and their application to solve the problems existing in the existing technology, significantly improve the quantity and quality of immune cells, enhance their anti-tumor function, and provide reliable technical support for clinical treatment. Summary of the invention

[0005] To this end, the present invention provides a method for preparing immune cells with anti-tumor function and application thereof, so as to solve the problems of insufficient efficacy, poor safety and insufficient individual adaptability of immune cell therapy in the prior art.

[0006] In order to achieve the above object, the present invention provides the following technical solutions: According to a first aspect of the present invention, there is provided a method for preparing immune cells having anti-tumor function, comprising the following steps: S1. Collect peripheral blood samples, isolate mononuclear cells, wash, count and evaluate cell viability; S2. inoculating the mononuclear cells into a bioreactor, culturing them in the bioreactor for 1 day using a first culture medium, then replacing the culture medium in the bioreactor, and continuing to culture the mononuclear cells in the bioreactor for 13-15 days using a second culture medium to obtain immune cells; S3. Starting from the 14th day after culture, immune cell activation was induced for 7 days; S4. Continue to expand the culture using the second culture medium and replenish the culture medium every 2-3 days to maintain the cell density at 1.8×10 6 cells / mL until clinical use.

[0007] Furthermore, the first culture medium comprises the following components: Basic cell culture medium dry powder 13-19g / L, glutamine 0.8-1.5g / L, growth factor 0.1-0.5mg / L, vitamin 12-22mg / L, insulin 3-8mg / L, albumin 2-6g / L, human transferrin 6-12mg / L, sodium bicarbonate 8-16g / L, GM-CSF 12-25ng / mL, IL-4 5-10ng / mL; In addition, 10% tumor cell lysate was added to the first culture medium.

[0008] Further, the second culture medium comprises the following components: serum-free lymphocyte culture medium 800-1000mL, 8-12% autologous plasma, Antrodia cinnamomea extract 0.5-1.5mg / mL, IFN-γ 800-1200IU / mL, IL-2 600-1200 IU / mL, selenium 0.03-0.06g / L, human serum albumin 22-26g / L, dithiothreitol 0.03-0.09μL / mL, L-arginine 100-300μg / mL, glucose 30-60μg / mL, sodium selenite 30-80μg / mL, transferrin 0.003-0.0055g / L; The Antrodia camphorata extract comprises Antrodia camphorata triterpenes, Antrodia camphorata polysaccharides and Antrodia camphorata alkaloids.

[0009] Furthermore, the preparation method of the Antrodia cinnamomea extract specifically comprises the following steps: A. Raw material pretreatment: drying, crushing and sieving the Antrodia cinnamomea mycelium to 20-30 mesh to obtain the crushed Antrodia cinnamomea mycelium; B. Supercritical CO2 extraction: The powder obtained in step A is placed in an extraction kettle and subjected to supercritical CO2 extraction. After extraction twice, the pH of the extract is adjusted to 2-4 with high-purity hydrochloric acid. The extracted extract is then passed through the first reactor and the second reactor in sequence to separate CO2 and obtain an extract. C. Dynamic reflux adsorption: The extract obtained in step B is subjected to dynamic reflux adsorption at a flow rate of 30-60 mL / min and a reflux time of 60-90 min. After the adsorption is completed, the permeate I is collected; the adsorption column used in the dynamic reflux adsorption is a macroporous resin HP-20 adsorption column; D. Segment elution: The first stage of elution: the eluent is pure water, the flow rate is 2-8mL / min, and the time is 30-60min; Second stage elution: the eluent is 10-20% ethanol (v / v), the flow rate is 2-8 mL / min, and the time is 30-60 min; The third stage of elution: the eluent is 30-40% ethanol (v / v), the flow rate is 2-8mL / min, and the time is 30-60min; The fourth stage of elution: the eluent is 90-95% ethanol (v / v), the flow rate is 0.5-5mL / min, and the elution time is 60-110min; The eluate II from the first three stages is combined and collected, and the eluate II contains Antrodia cinnamomea polysaccharide and Antrodia cinnamomea alkaloid extract; Collecting the fourth stage eluate III, which is a concentrated solution of Antrodia cinnamomea triterpenes; E. Combine the penetration solution I, eluent II and eluent III, add 95% ethanol for alcohol precipitation, and then filter, dry and crush to obtain the Antrodia cinnamomea extract.

[0010] Furthermore, the extraction method in B is to extract twice: The first extraction conditions are: extraction temperature 45-60°C, extraction pressure 22-26MPa, extraction time 6-9min, and 60-80% volume fraction of ethanol as auxiliary solvent; The second extraction conditions are as follows: extraction temperature of 40-45° C., extraction pressure of 23-28 MPa, extraction time of 4-6 min, and 70-90% by volume ethanol as an auxiliary solvent.

[0011] Furthermore, in B, the specific operation of separating CO2 is as follows: the temperature of the first reactor is 35-39°C, the pressure is 13-18MPa, and the time is 4-8min; the temperature of the second reactor is 30-36°C, the pressure is 10-15MPa, and the time is 2-6min.

[0012] Furthermore, the tumor cell lysate is a lysate selected from cancer tumor cells, and the cancer is selected from the following group: breast cancer, small cell lung cancer, non-small cell lung cancer, glioma, medulloblastoma, neuroblastoma, Wilms tumor, rhabdomyosarcoma, osteosarcoma, liver cancer, pancreatic cancer, melanoma, prostate cancer or ocular melanoma.

[0013] Furthermore, the preparation method of the tumor cell lysate is as follows: The tumor cells were heat-shocked at 42°C for 30 min, rapidly cooled to -80°C for 8-12 min, and then thawed at 18-22°C for 2-3 min. The above freezing and thawing process was repeated at least 3 times before centrifugal filtration.

[0014] According to a second aspect of the present invention, an immune cell prepared according to the above method is provided.

[0015] According to a third aspect of the present invention, there is provided use of the above-mentioned immune cells in the preparation of a preparation for improving autoimmune diseases.

[0016] The present invention has the following advantages: 1. The present application provides an efficient method for preparing immune cells with anti-tumor function. Through an optimized culture method and a specifically designed first culture medium and a second culture medium, combined with the preparation process of Antrodia cinnamomea extract, the optimized culture method and culture medium significantly increase the proportion, cell viability and expansion multiple of NK cells, thereby improving the culture effect of immune cells.

[0017] 2. Adding tumor cell lysate to the first culture medium of the present application can effectively activate immune cells, increase their proportion, viability and amplification multiples, and the tumor cell lysate of the present application is prepared by heat shock and freeze-thaw lysis, ensuring that the antigen components in the lysate are fully released, thereby enhancing the recognition and attack capabilities of immune cells.

[0018] 3. The second culture medium of the present application is added with Antrodia cinnamomea extract, which contains Antrodia cinnamomea triterpenes, polysaccharides and alkaloids, further enhancing the function of immune cells and improving their anti-tumor effect. The preparation of Antrodia cinnamomea extract also combines supercritical CO2 extraction technology and dynamic reflux adsorption technology to ensure the purity and activity of the extract, thereby improving the culture efficiency and quality of immune cells. DETAILED DESCRIPTION

[0019] The following is a description of the implementation of the present invention by specific embodiments. People familiar with the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0020] The present invention provides a method for preparing immune cells with anti-tumor function, comprising the following steps: S1. Collect peripheral blood samples, isolate mononuclear cells, wash, count and evaluate cell viability; S2. inoculating the mononuclear cells into a bioreactor, culturing them in the bioreactor for 1 day using a first culture medium, then replacing the culture medium in the bioreactor, and continuing to culture the mononuclear cells in the bioreactor for 13-15 days using a second culture medium to obtain immune cells; S3. Starting from the 14th day after culture, immune cell activation was induced for 7 days; S4. Continue to expand the culture using the second culture medium and replenish the culture medium every 2-3 days to maintain the cell density at 1.8×10 6 cells / mL until clinical use.

[0021] Specifically, the first culture medium includes the following components: Basic cell culture medium dry powder 13-19g / L, glutamine 0.8-1.5g / L, growth factor 0.1-0.5mg / L, vitamin 12-22mg / L, insulin 3-8mg / L, albumin 2-6g / L, human transferrin 6-12mg / L, sodium bicarbonate 8-16g / L, GM-CSF 12-25ng / mL, IL-4 5-10ng / mL; In addition, 10% tumor cell lysate was added to the first culture medium.

[0022] Specifically, the second culture medium includes the following components: serum-free lymphocyte culture medium 800-1000mL, 8-12% autologous plasma, Antrodia cinnamomea extract 0.5-1.5mg / mL, IFN-γ 800-1200IU / mL, IL-2 600-1200 IU / mL, selenium 0.03-0.06g / L, human serum albumin 22-26g / L, dithiothreitol 0.03-0.09μL / mL, L-arginine 100-300μg / mL, glucose 30-60μg / mL, sodium selenite 30-80μg / mL, transferrin 0.003-0.0055g / L; The Antrodia cinnamomea extract comprises Antrodia cinnamomea triterpenes, Antrodia cinnamomea polysaccharides and Antrodia cinnamomea alkaloids. The preparation method of the Antrodia cinnamomea extract specifically comprises the following steps: A. Raw material pretreatment: drying, crushing and sieving the Antrodia cinnamomea mycelium to 20-30 mesh to obtain the crushed Antrodia cinnamomea mycelium; B. Supercritical CO2 extraction: The powder obtained in step A is placed in an extraction kettle and subjected to supercritical CO2 extraction. After extraction twice, the pH of the extract is adjusted to 2-4 with high-purity hydrochloric acid. The extracted extract is then passed through the first reactor and the second reactor in sequence to separate CO2 and obtain an extract. C. Dynamic reflux adsorption: The extract obtained in step B is subjected to dynamic reflux adsorption at a flow rate of 30-60 mL / min and a reflux time of 60-90 min. After the adsorption is completed, the permeate I is collected; the adsorption column used in the dynamic reflux adsorption is a macroporous resin HP-20 adsorption column; D. Segment elution: The first stage of elution: the eluent is pure water, the flow rate is 2-8mL / min, and the time is 30-60min; Second stage elution: the eluent is 10-20% ethanol (v / v), the flow rate is 2-8 mL / min, and the time is 30-60 min; The third stage of elution: the eluent is 30-40% ethanol (v / v), the flow rate is 2-8mL / min, and the time is 30-60min; The fourth stage of elution: the eluent is 90-95% ethanol (v / v), the flow rate is 0.5-5mL / min, and the elution time is 60-110min; The eluate II from the first three stages is combined and collected, and the eluate II contains Antrodia cinnamomea polysaccharide and Antrodia cinnamomea alkaloid extract; Collecting the fourth stage eluate III, which is a concentrated solution of Antrodia cinnamomea triterpenes; E. Combine the penetration solution I, eluent II and eluent III, add 95% ethanol for alcohol precipitation, and then filter, dry and crush to obtain the Antrodia cinnamomea extract.

[0023] Specifically, the extraction method in B is to extract twice: The first extraction conditions are: extraction temperature 45-60°C, extraction pressure 22-26MPa, extraction time 6-9min, and 60-80% volume fraction of ethanol as auxiliary solvent; The second extraction conditions are as follows: extraction temperature of 40-45° C., extraction pressure of 23-28 MPa, extraction time of 4-6 min, and 70-90% by volume ethanol as an auxiliary solvent.

[0024] Specifically, the specific operation of separating CO2 in step B is as follows: the temperature of the first reactor is 35-39°C, the pressure is 13-18MPa, and the time is 4-8min; the temperature of the second reactor is 30-36°C, the pressure is 10-15MPa, and the time is 2-6min.

[0025] Tumor cell lysate is a lysate selected from cancer tumor cells, wherein the cancer is selected from the following group: breast cancer, small cell lung cancer, non-small cell lung cancer, glioma, medulloblastoma, neuroblastoma, Wilms tumor, rhabdomyosarcoma, osteosarcoma, liver cancer, pancreatic cancer, melanoma, prostate cancer or ocular melanoma. The lysate of liver cancer tumor cells is selected in this application.

[0026] The preparation method of tumor cell lysate is as follows: The tumor cells were heat-shocked at 42°C for 30 min, rapidly cooled to -80°C for 8-12 min, and then thawed at 18-22°C for 2-3 min. The above freezing and thawing process was repeated at least 3 times before centrifugal filtration.

[0027] The present invention provides an immune cell prepared according to the above method.

[0028] The present invention provides the use of the above immune cells in preparing a preparation for improving autoimmune diseases.

[0029] Example 1 This embodiment provides a method for preparing immune cells with anti-tumor function, comprising: S1. Collect peripheral blood samples, isolate mononuclear cells, wash, count and evaluate cell viability; S2. The mononuclear cells are inoculated into a bioreactor, a first culture medium is added and cultured in the bioreactor for 1 day, and then the culture medium in the bioreactor is replaced, and the mononuclear cells in S2 are cultured in the bioreactor for 14 days using a second culture medium to obtain immune cells; S3. Starting from the 14th day after culture, immune cell activation was induced for 7 days; S4. Continue to expand the culture using the second culture medium and replenish the culture medium every 2-3 days to maintain the cell density at 1.8×10 6 cells / mL until clinical use.

[0030] Wherein, the first culture medium comprises the following components: Basic cell culture medium dry powder 17g / L, glutamine 1.3g / L, growth factor 0.3mg / L, vitamin 19mg / L, insulin 6mg / L, albumin 4g / L, human transferrin 9mg / L, sodium bicarbonate 12g / L, GM-CSF 18.5ng / mL, IL-48ng / mL; In addition, 10% tumor cell lysate was added to the first culture medium.

[0031] The second culture medium includes the following components: serum-free lymphocyte culture medium 900 mL, autologous plasma 100 mL, Antrodia cinnamomea extract 1 mg / mL, IFN-γ 1000 IU / mL, IL-2 900 IU / mL, selenium 0.05 g / L, human serum albumin 24 g / L, dithiothreitol 0.06 μL / mL, L-arginine 200 μg / mL, glucose 45 μg / mL, sodium selenite 60 μg / mL, and transferrin 0.004 g / L. The Antrodia camphorata extract includes Antrodia camphorata triterpenes, Antrodia camphorata polysaccharides and Antrodia camphorata alkaloids.

[0032] Specifically, the preparation method of Antrodia cinnamomea extract comprises the following steps: A. Raw material pretreatment: drying, crushing and sieving the Antrodia cinnamomea mycelium to 25 meshes to obtain the crushed Antrodia cinnamomea mycelium; B. Supercritical CO2 extraction: The powder obtained in step A is placed in an extraction kettle and subjected to supercritical CO2 extraction for 2 times: the first time is at an extraction temperature of 50°C, an extraction pressure of 24MPa, an extraction time of 7min, and an auxiliary solvent of 75% ethanol by volume; the second time is at an extraction temperature of 43°C, an extraction pressure of 26MPa, an extraction time of 5min, and an auxiliary solvent of 85% ethanol by volume; the pH of the extract is then adjusted to 3 with high-purity hydrochloric acid, and the extracted extract is then passed through a first reactor and a second reactor in sequence, the temperature of the first reactor being 37°C, the pressure being 16MPa, and the time being 6min, and the temperature of the second reactor being 33°C, the pressure being 13MPa, and the time being 4min, to obtain an extract after CO2 is separated; C. Dynamic reflux adsorption: The extract obtained in step B was subjected to dynamic reflux adsorption at a flow rate of 45 mL / min and a reflux time of 75 min. After the adsorption was completed, the permeate I was collected; the adsorption column used in the dynamic reflux adsorption was a macroporous resin HP-20 adsorption column; D. Segment elution: The first stage of elution: the eluent is pure water, the flow rate is 4 mL / min, and the time is 50 min; Second stage elution: the eluent is 15% ethanol (v / v), the flow rate is 5 mL / min, and the time is 50 min; The third stage of elution: the eluent is 35% ethanol (v / v), the flow rate is 6 mL / min, and the time is 50 min; The fourth stage of elution: the eluent is 95% ethanol (v / v), the flow rate is 2 mL / min, and the elution time is 100 min; The eluents II of the first three stages are combined and collected, and the eluent II contains Antrodia cinnamomea polysaccharides and Antrodia cinnamomea alkaloid extracts; the eluent III of the fourth stage is collected, and the eluent III is a concentrated solution of Antrodia cinnamomea triterpenes; E. Combine the penetration solution I, eluent II and eluent III, add 95% ethanol (v / v) for alcohol precipitation, and then filter, dry and crush to obtain the Antrodia cinnamomea extract.

[0033] Wherein, the tumor cell lysate in the first culture medium is selected from the lysate of liver cancer tumor cells.

[0034] The preparation method of tumor cell lysate is as follows: The tumor cells were heat-shocked at 42°C for 30 min, and then rapidly cooled to -80°C for 10 min, and then thawed at 20°C for 3 min. The freezing and thawing process was repeated at least 3 times before centrifugation and filtration to ensure the purity of the lysate.

[0035] Example 2 This embodiment provides a method for preparing immune cells with anti-tumor function, comprising: S1. Collect peripheral blood samples, isolate mononuclear cells, wash, count and evaluate cell viability; S2. The mononuclear cells are inoculated into a bioreactor, a first culture medium is added and cultured in the bioreactor for 1 day, and then the culture medium in the bioreactor is replaced, and the mononuclear cells in S2 are cultured in the bioreactor for 14 days using a second culture medium to obtain immune cells; S3. Starting from the 14th day after culture, immune cell activation was induced for 7 days; S4. Continue to expand the culture using the second culture medium and replenish the culture medium every 2-3 days to maintain the cell density at 1.8×10 6 cells / mL until clinical use.

[0036] Wherein, the first culture medium comprises the following components: Basic cell culture medium dry powder 17g / L, glutamine 1.3g / L, growth factor 0.3mg / L, vitamin 19mg / L, insulin 6mg / L, albumin 4g / L, human transferrin 9mg / L, sodium bicarbonate 12g / L, GM-CSF 18.5ng / mL, IL-48ng / mL; In addition, 10% tumor cell lysate was added to the first culture medium.

[0037] The second culture medium includes the following components: serum-free lymphocyte culture medium 900 mL, autologous plasma 100 mL, Antrodia cinnamomea extract 0.5 mg / mL, IFN-γ 1000 IU / mL, IL-2 900 IU / mL, selenium 0.05 g / L, human albumin 24 g / L, dithiothreitol 0.06 μL / mL, L-arginine 200 μg / mL, glucose 45 μg / mL, sodium selenite 60 μg / mL, and transferrin 0.004 g / L. The Antrodia camphorata extract includes Antrodia camphorata triterpenes, Antrodia camphorata polysaccharides and Antrodia camphorata alkaloids.

[0038] Specifically, the preparation method of Antrodia cinnamomea extract comprises the following steps: A. Raw material pretreatment: drying, crushing and sieving the Antrodia cinnamomea mycelium to 25 mesh to obtain the crushed Antrodia cinnamomea mycelium; B. Supercritical CO2 extraction: The powder obtained in step A is placed in an extraction kettle and subjected to supercritical CO2 extraction for 2 times: the first time is at an extraction temperature of 50°C, an extraction pressure of 24MPa, an extraction time of 7min, and an auxiliary solvent of 75% ethanol by volume; the second time is at an extraction temperature of 43°C, an extraction pressure of 26MPa, an extraction time of 5min, and an auxiliary solvent of 85% ethanol by volume; the pH of the extract is then adjusted to 3 with high-purity hydrochloric acid, and the extracted extract is then passed through a first reactor and a second reactor in sequence, the temperature of the first reactor being 37°C, the pressure being 16MPa, and the time being 6min, and the temperature of the second reactor being 33°C, the pressure being 13MPa, and the time being 4min, to obtain an extract after CO2 is separated; C. Dynamic reflux adsorption: The extract obtained in step B was subjected to dynamic reflux adsorption at a flow rate of 45 mL / min and a reflux time of 75 min. After the adsorption was completed, the permeate I was collected; the adsorption column used in the dynamic reflux adsorption was a macroporous resin HP-20 adsorption column; D. Segment elution: The first stage of elution: the eluent is pure water, the flow rate is 4 mL / min, and the time is 50 min; The second stage of elution: the eluent is 15% ethanol (v / v), the flow rate is 5 mL / min, and the time is 50 min; The third stage of elution: the eluent is 35% ethanol (v / v), the flow rate is 6 mL / min, and the time is 50 min; The fourth stage of elution: the eluent is 95% ethanol (v / v), the flow rate is 2 mL / min, and the elution time is 100 min; The eluate II from the first three stages is combined and collected, and the eluate II contains Antrodia cinnamomea polysaccharide and Antrodia cinnamomea alkaloid extract; Collecting the fourth stage eluate III, which is a concentrated solution of Antrodia cinnamomea triterpenes; E. Combine the penetration solution I, eluent II and eluent III, add 95% ethanol (v / v) for alcohol precipitation, and then filter, dry and crush to obtain the Antrodia cinnamomea extract.

[0039] Example 3 This embodiment provides a method for preparing immune cells with anti-tumor function, comprising: S1. Collect peripheral blood samples, separate mononuclear cells, wash, count and evaluate cell viability; S2. Inoculate the mononuclear cells into a bioreactor, add a first culture medium and culture them in the bioreactor for 1 day, then replace the culture medium in the bioreactor, and continue to culture the mononuclear cells in S2 in the bioreactor for 14 days using a second culture medium to obtain immune cells; S3. Starting from the 14th day after culture, immune cell activation was induced for 7 days; S4. Continue to expand the culture using the second culture medium and replenish the culture medium every 2-3 days to maintain the cell density at 1.8×10 6 cells / mL until clinical use.

[0040] Wherein, the first culture medium comprises the following components: Basic cell culture medium dry powder 17g / L, glutamine 1.3g / L, growth factor 0.3mg / L, vitamin 19mg / L, insulin 6mg / L, albumin 4g / L, human transferrin 9mg / L, sodium bicarbonate 12g / L, GM-CSF 18.5ng / mL, IL-48ng / mL; In addition, 10% tumor cell lysate was added to the first culture medium.

[0041] The second culture medium includes the following components: serum-free lymphocyte culture medium 900 mL, autologous plasma 100 mL, Antrodia cinnamomea extract 1.5 mg / mL, IFN-γ 1000 IU / mL, IL-2 900 IU / mL, selenium 0.05 g / L, human albumin 24 g / L, dithiothreitol 0.06 μL / mL, L-arginine 200 μg / mL, glucose 45 μg / mL, sodium selenite 60 μg / mL, and transferrin 0.004 g / L. The Antrodia camphorata extract includes Antrodia camphorata triterpenes, Antrodia camphorata polysaccharides and Antrodia camphorata alkaloids.

[0042] Specifically, the preparation method of Antrodia cinnamomea extract comprises the following steps: A. Raw material pretreatment: drying, crushing and sieving the Antrodia cinnamomea mycelium to 25 mesh to obtain the crushed Antrodia cinnamomea mycelium; B. Supercritical CO2 extraction: The powder obtained in step A is placed in an extraction kettle and subjected to supercritical CO2 extraction for 2 times: the first time is at an extraction temperature of 50°C, an extraction pressure of 24MPa, an extraction time of 7min, and an auxiliary solvent is 75% ethanol by volume; the second time is at an extraction temperature of 43°C, an extraction pressure of 26MPa, an extraction time of 5min, and an auxiliary solvent is 85% ethanol by volume; the pH of the extract is then adjusted to 3 with high-purity hydrochloric acid, and the extracted extract is then passed through the first reactor and the second reactor in sequence, the temperature of the first reactor is 37°C, the pressure is 16MPa, and the time is 6min, and the temperature of the second reactor is 33°C, the pressure is 13MPa, and the time is 4min, to obtain the extract after CO2 is separated; C. Dynamic reflux adsorption: The extract obtained in step B is subjected to dynamic reflux adsorption at a flow rate of 45mL / min and a reflux time of 75min. After the adsorption is completed, the penetration liquid I is collected; the adsorption column used in the dynamic reflux adsorption is a macroporous resin HP-20 adsorption column; D. Segment elution: The first stage of elution: the eluent is pure water, the flow rate is 4 mL / min, and the time is 50 min; The second stage of elution: the eluent is 15% ethanol (v / v), the flow rate is 5 mL / min, and the time is 50 min; The third stage of elution: the eluent is 35% ethanol (v / v), the flow rate is 6 mL / min, and the time is 50 min; The fourth stage of elution: the eluent is 95% ethanol (v / v), the flow rate is 2 mL / min, and the elution time is 100 min; The eluate II from the first three stages is combined and collected, and the eluate II contains Antrodia cinnamomea polysaccharide and Antrodia cinnamomea alkaloid extract; Collecting the fourth stage eluate III, which is a concentrated solution of Antrodia cinnamomea triterpenes; E. Combine the penetration solution I, eluent II and eluent III, add 95% ethanol (v / v) for alcohol precipitation, and then filter, dry and crush to obtain the Antrodia cinnamomea extract.

[0043] Comparative Example 1: This example is a comparative example of Example 1, except that the tumor cell lysate in the first culture medium is removed, and the other steps and parameters are the same as those in Example 1.

[0044] Comparative Example 2: This example is used as a comparative example of Example 1, except that the Antrodia cinnamomea extract in the second culture medium is removed, and the other steps and parameters are the same as those in Example 1.

[0045] Test Example: The NK cell ratio, cell viability, and expansion multiple of Example 1-3 and Comparative Example 1-2 are shown in Table 1.

[0046] Table 1 Effects of different culture media on NK cell proportion, viability and expansion multiple

[0047] From the data in the above table, it can be seen that the following conclusions can be drawn based on Examples 1-3 and Comparative Examples 1-2 and the table data: 1. Comparison between Example 1 and Comparative Example 1 shows that the NK cell ratio of Example 1 is 98.86%, while that of Comparative Example 1 is only 77.45%; the cell viability of Example 1 is 99.56%, while that of Comparative Example 1 is 96.78%; the expansion multiple of Example 1 is 283 times, while that of Comparative Example 1 is 265 times. Adding 10% of tumor cell lysate to the first culture medium significantly increases the ratio, cell viability and expansion multiple of NK cells.

[0048] 2. The comparison between Example 1 and Comparative Example 2 shows that the NK cell ratio of Example 1 is 98.86%, while that of Comparative Example 2 is 81.02%; the cell viability of Example 1 is 99.56%, while that of Comparative Example 2 is 95.83%; the expansion multiple of Example 1 is 283 times, while that of Comparative Example 2 is 231 times. From this and the data comparison of Examples 1-3, it can be proved that the addition of Antrodia cinnamomea extract to the second culture medium significantly increases the ratio, cell viability and expansion multiple of NK cells, and different concentrations of Antrodia cinnamomea extract have a significant effect on the ratio, cell viability and expansion multiple of NK cells, with the concentration of 1 mg / mL performing best.

[0049] Through the method of the present application, a large number of high-quality NK cells can be obtained in a relatively short period of time. A high proportion of NK cells means that more cells can participate in the anti-tumor response, improving the overall killing ability of the immune system. NK cells with high activity rates can maintain their killing function in the body for a longer period of time, prolonging the time of their anti-tumor effect. A large number of NK cells can be rapidly expanded in a short period of time, providing a sufficient number of cells for clinical treatment. The addition of tumor cell lysate to the first culture medium and Antrodia cinnamomea extract to the second culture medium significantly increased the proportion, cell viability and expansion multiple of NK cells, verifying that the technical solution of the present application significantly improves the anti-tumor ability of immune cells by enhancing the function of NK cells, providing a reliable cell source and technical support for clinical treatment.

[0050] Although the present invention has been described in detail above by general description and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.

Claims

1. A method for preparing immune cells with anti-tumor function, characterized in that: The following steps are involved: S1. Collect peripheral blood samples, isolate mononuclear cells, wash, count and evaluate cell viability; S2. inoculating the mononuclear cells into a bioreactor, culturing them in the bioreactor for 1 day using a first culture medium, then replacing the culture medium in the bioreactor, and continuing to culture the mononuclear cells in the bioreactor for 13-15 days using a second culture medium to obtain immune cells; S3. Starting from the 14th day after culture, immune cell activation was induced for 7 days; S4. Continue to expand the culture using the second culture medium and replenish the culture medium every 2-3 days to maintain the cell density at 1.8×10 6 cells / mL until clinical use.

2. The method for preparing immune cells with anti-tumor function according to claim 1, characterized in that: The first culture medium comprises the following components: Basic cell culture medium dry powder 13-19g / L, glutamine 0.8-1.5g / L, growth factor 0.1-0.5mg / L, vitamin 12-22mg / L, insulin 3-8mg / L, albumin 2-6g / L, human transferrin 6-12mg / L, sodium bicarbonate 8-16g / L, GM-CSF 12-25ng / mL, IL-4 5-10ng / mL; In addition, 10% tumor cell lysate was added to the first culture medium.

3. The method for preparing immune cells with anti-tumor function according to claim 1, characterized in that: The second culture medium comprises the following components: Serum-free lymphocyte culture medium 800-1000mL, 8-12% autologous plasma, Antrodia cinnamomea extract 0.5-1.5mg / mL, IFN-γ 800-1200IU / mL, IL-2 600-1200 IU / mL, selenium 0.03-0.06g / L, human serum albumin 22-26g / L, dimercaptoethanol 0.03-0.09μL / mL, L-arginine 100-300μg / mL, glucose 30-60μg / mL, sodium selenite 30-80μg / mL, transferrin 0.003-0.0055g / L; The Antrodia camphorata extract comprises Antrodia camphorata triterpenes, Antrodia camphorata polysaccharides and Antrodia camphorata alkaloids.

4. The method for preparing immune cells with anti-tumor function according to claim 3, characterized in that: The preparation method of the Antrodia cinnamomea extract specifically comprises the following steps: A. Raw material pretreatment: drying, crushing and sieving the Antrodia cinnamomea mycelium to 20-30 mesh to obtain the crushed Antrodia cinnamomea mycelium; B. Supercritical CO2 extraction: The powder obtained in step A is placed in an extraction kettle and subjected to supercritical CO2 extraction. After extraction twice, the pH of the extract is adjusted to 2-4 with high-purity hydrochloric acid. The extracted extract is then passed through the first reactor and the second reactor in sequence to separate CO2 and obtain an extract. C. Dynamic reflux adsorption: The extract obtained in step B is subjected to dynamic reflux adsorption at a flow rate of 30-60 mL / min and a reflux time of 60-90 min. After the adsorption is completed, the permeate I is collected; the adsorption column used in the dynamic reflux adsorption is a macroporous resin HP-20 adsorption column; D. Segment elution: The first stage of elution: the eluent is pure water, the flow rate is 2-8mL / min, and the time is 30-60min; Second stage elution: the eluent is 10-20% ethanol (v / v), the flow rate is 2-8 mL / min, and the time is 30-60 min; The third stage of elution: the eluent is 30-40% ethanol (v / v), the flow rate is 2-8mL / min, and the time is 30-60min; The fourth stage of elution: the eluent is 90-95% ethanol (v / v), the flow rate is 0.5-5mL / min, and the elution time is 60-110min; The eluate II from the first three stages is combined and collected, and the eluate II contains Antrodia cinnamomea polysaccharide and Antrodia cinnamomea alkaloid extract; Collecting the fourth stage eluate III, which is a concentrated solution of Antrodia cinnamomea triterpenes; E. Combine the penetration solution I, eluent II and eluent III, add 95% ethanol for alcohol precipitation, and then filter, dry and crush to obtain the Antrodia cinnamomea extract.

5. The method for preparing immune cells with anti-tumor function according to claim 4, characterized in that: The extraction method in B is to extract twice: The first extraction conditions are: extraction temperature 45-60°C, extraction pressure 22-26MPa, extraction time 6-9min, and 60-80% volume fraction of ethanol as auxiliary solvent; The second extraction conditions are as follows: extraction temperature of 40-45° C., extraction pressure of 23-28 MPa, extraction time of 4-6 min, and 70-90% by volume ethanol as an auxiliary solvent.

6. The method for preparing immune cells with anti-tumor function according to claim 5, characterized in that: In B, the specific operation of separating CO2 is as follows: the temperature of the first reactor is 35-39°C, the pressure is 13-18MPa, and the time is 4-8min; the temperature of the second reactor is 30-36°C, the pressure is 10-15MPa, and the time is 2-6min.

7. The method for preparing immune cells with anti-tumor function according to claim 2, characterized in that: The tumor cell lysate is a lysate selected from cancer tumor cells, and the cancer is selected from the following group: breast cancer, small cell lung cancer, non-small cell lung cancer, glioma, medulloblastoma, neuroblastoma, Wilms tumor, rhabdomyosarcoma, osteosarcoma, liver cancer, pancreatic cancer, melanoma, prostate cancer or ocular melanoma.

8. The method for preparing immune cells with anti-tumor function according to claim 7, characterized in that: The preparation method of the tumor cell lysate is specifically as follows: The tumor cells were heat-shocked at 42°C for 30 min, rapidly cooled to -80°C for 8-12 min, and then thawed at 18-22°C for 2-3 min. The above freezing and thawing process was repeated at least 3 times before centrifugal filtration.

9. An immune cell prepared according to the method according to any one of claims 1 to 8.

10. Use of the immune cells according to claim 9 in the preparation of a preparation for improving autoimmune diseases.

Citation Information

Patent Citations

  • Antrodia camphorate extract having human body immunity enhancing function, and its application

    CN104208106A

  • Immune cell and preparation method thereof

    CN105039254A

  • Immune cell and application thereof in preparation of medicine with anti-tumor effect

    CN117511869A

  • Composition of antrodia cinnamomea solid cultured mycelium and water / alcohol extract of fruiting body used in cancer inhibition

    TW201726154A